Cardiovascular risk factors, cortisol, and amyloid‐β deposition in Alzheimer's Disease Neuroimaging Initiative
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Background: There is epidemiological evidence that cardiovascular risk factors (CVRF) also are risk factors for Alzheimer's disease, but there is limited information on this from neuropathological studies, and even less from in vivo studies. Therefore, we examined the relationship between CVRF and amyloid‐β (Aβ) brain burden measured by Pittsburgh Compound B‐positron emission tomography (PiB‐PET) studies in the Alzheimer's Disease Neuroimaging Initiative. Methods: Ninety‐nine subjects from the Alzheimer's Disease Neuroimaging Initiative cohort who had a PiB‐PET study measure, apolipoprotein E genotyping data, and information available on CVRF (body mass index [BMI], systolic blood pressure, diastolic blood pressure [DBP], and cholesterol and fasting glucose test results) were included. Eighty‐one subjects also had plasma cortisol, C‐reactive protein, and superoxide dismutase 1 measurements. Stepwise regression models were used to assess the relation between the CVRF and the composite PiB‐PET score. Results: The first model included the following as baseline variables: age, clinical diagnosis, number of apolipoprotein ε4 alleles, BMI (P = .023), and DBP (P = .012). BMI showed an inverse relation with PiB‐PET score, and DBP had a positive relation with PiB‐PET score. In the second adjusted model, cortisol plasma levels were also associated with PiB‐PET score (P = .004). Systolic blood pressure, cholesterol, or impaired fasting glucose were not found to be associated with PiB‐PET values. Conclusion: In this cross‐sectional study, we found an association between Aβ brain burden measured in vivo and DBP and cortisol, indicating a possible link between these CVRF and Aβ burden measured by PiB‐PET. These findings highlight the utility of biomarkers to explore potential pathways linking diverse Alzheimer's disease risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
Self-citationCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationRevising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · cited 1×
“…of AD begin to appear decades before symptom onset [4], and long before the dementia stage is reached, there is a preclinical phase of many years’ duration, during which the two signature lesions of AD—amyloid-b (A b ) deposits and fibrillar tau lesions—progressively accumulate in the brain [5,6].”
15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726 · cited 1×
“…for finding only an association with DBP can be that the blood pressure decrease that occurs at presymptomatic stages of AD mainly affects SBP [13], and that DBP changes are not so affected by disease evolution [44], so that in the regression model SBP does not add any additional information to DBP.”
Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207
Anstey, K. J., Cherbuin, N., Budge, M., & Young, J. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00825.x · Cited by 855 · cited 1×
“Many of these RF were previously acknowledged as cardiovascular risk factors (CVRF), but there is also evidence that hypertension [7,8], obesity [9], and diabetes [8,10,11] increase the risk of AD.”
The pathological process underlying Alzheimer’s disease in individuals under thirty
Braak, H., & Del Tredici, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-010-0789-4 · Cited by 812 · cited 1×
“We now know that pathological hallmarks of AD begin to appear decades before symptom onset [4], and long before the dementia stage is reached, there is a preclinical phase of many years’ duration, during which the two signature lesions of AD—amyloid-b (A b ) deposits and fibrillar tau…”
Glucocorticoids increase amyloid-β and tau pathology in a mouse model of alzheimer’s disease
Green, K. N., Billings, L. M., Roozendaal, B., McGaugh, J. L., & LaFerla, F. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2797-06.2006 · Cited by 623
Edison, P., Archer, H. A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F. E., Hammers, A., Tai, Y. F., Fox, N., Kennedy, A., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.08.001 · Cited by 513 · cited 1×
“This is in agreement with a recent imaging and autopsy study that found no correlation between a marker of activated microglia ( 3 H-PK11195) and PiB-PET scores [51], whereas the results of in vivo studies are conflicting [52–54].”
Zhang, X., Zhou, K., Wang, R., Cui, J., Lipton, S. A., Liao, F.-F., Xu, H., & Zhang, Y.-W. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608856200 · Cited by 436
Cited by
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Iturria-Medina, Y., Sotero, R. C., Toussaint, P. J., Mateos-Pérez, J. M., Evans, A. C., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., et al. (2016) · Nature Communications · doi:10.1038/ncomms11934 · Cited by 1,202
Self-citationAlzheimer’s disease: risk factors and potentially protective measures
Silva, M. V. F., Loures, C. D. M. G., Alves, L. C. V., de Souza, L. C., Borges, K. B. G., & Carvalho, M. D. G. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0524-y · Cited by 937
Toledo, J. B., Arnold, S. E., Raible, K., Brettschneider, J., Xie, S. X., Grossman, M., Monsell, S. E., Kukull, W. A., & Trojanowski, J. Q. (2013) · Brain · doi:10.1093/brain/awt188 · Cited by 849
Self-citationIadecola, C., Yaffe, K., Biller, J., Bratzke, L. C., Faraci, F. M., Gorelick, P. B., Gulati, M., Kamel, H., Knopman, D. S., Launer, L. J., et al. (2016) · Hypertension · doi:10.1161/hyp.0000000000000053 · Cited by 746
Metadata
- Authors
- Toledo, J. B., Toledo, E., Weiner, M. W., Jack, C. R., Jagust, W., Lee, V. M. ‐., Shaw, L. M., & Trojanowski, J. Q.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2012-11
- Volume
- 8
- Issue
- 6
- Pages
- 483-489
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2076385524
- Cited by
- 130
- References
- 20
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiovascular risk factors, cortisol, and amyloid‐β deposition in Alzheimer's Disease Neuroimaging Initiative. https://app.cochat.ai/papers/10.1016/j.jalz.2011.08.008
- The paper
- Toledo, J. B., Toledo, E., Weiner, M. W., Jack, C. R., Jagust, W., Lee, V. M. ‐., Shaw, L. M., & Trojanowski, J. Q. (2012). Cardiovascular risk factors, cortisol, and amyloid‐β deposition in Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2011.08.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.